Abstract: Gold nanoparticles (GNPs) have gained in prominence within the field of nanomedicine with recent advancement of several embodiments to clinical trials. To ensure their success in the clinic it has become increasingly clear that a deeper understanding of the biological interactions of GNPs is imperative. Since the majority of GNPs are intended for systemic intravenous use, an immediate and critical biological interaction is between the blood and the GNP. Blood is composed of plasma proteins and cells. Both of these components can induce downstream effects upon interacting with GNPs that ultimately influence their medical impact. For instance, proteins from the blood can cover the GNP to create a biological identity through formation of a protein corona that is quite different from the originally synthesized GNP. Once in the bloodstream this protein coated GNP evokes both positive and negative physiological responses such as biodistribution into tissue for therapy (i.e., cancer) and toxicity or off target accumulation in the reticuloendothelial system (RES) that must be controlled for optimal use. In this review, we summarize predominantly in vitro studies of GNP interactions with blood plasma proteins and blood cells and make the case that more in vivo study is urgently needed to optimal design and control GNP use in medicine. In some cases where no specific GNP blood studies exist, we draw the readers ' attention to studies conducted with other types of nanoparticles as reference.
Introduction
Although many metallic nanoparticles (NPs) are being investigated for clinical applications, gold based NPs (GNPs) have emerged as a dominant NP system for clinical use [1 -4] . This is in part due to a long history of gold use in medicine [5] . For instance, gold sodium thiomalate and gold thioglucose, two antiarthritic gold(I) thiolates, have been in active clinical use for some time [5] . Further, the easy synthesis and surface chemistry, unique optical properties and existing safety data of gold in humans have more recently made GNPs an attractive choice for a wide range of nanomedical applications, including drug delivery [6] and photothermal cancer therapy [7] . These studies supported the development of AurImmune ™ and AuroLase ™ GNP products now in clinical trials as stand alone cancer therapeutics with more in the pipeline [3, 8] . Reproducible synthesis in a variety of sizes and shapes, essentially limitless opportunities for surface functionalization and emerging techniques for optical and other modes of detection and activation have made gold a leading candidate for therapeutic nanomedicine.
Despite this growth in GNP use, in vivo biodistribution and interactions of GNPs with biological components, especially blood, are not well understood. A recent review shows a significant lack of correlation between in vitro uptake and in vivo biodistribution and toxicity studies and no clear understanding of how GNP physicochemical properties affect these outcomes [4] . This work included a review of colloids, rods, shells and other multifunctional GNP forms with broad summary points below: 1. The majority of in vivo biodistribution work is carried out in mice and rat models with single intravenous in jection and variety of GNP doses ( μ g gold/g of animal).
Most intravenously injected GNPs are spherical in
shape and coated with a polymer poly-ethylene glycol (PEG), which is believed to increase the blood circulation time of NPs by reduction in uptake by the organs of reticuloendothelial system (RES) including liver and spleen.
3. Excretion from the body and crossing of blood brain barrier (BBB) is particle size dependent. GNPs < 15 nm in size can cross BBB, and < 10 nm size can be excreted via kidney. 4. For GNPs of size 10 -100 nm, the primary accumulation site is liver and spleen regardless of their size, shape, and surface functionalization. 5. In vivo studies on the mechanism of GNP biodistribution, interactions with the immune system, and toxicity are rare and controversial.
Noticeably absent from the above review and others is description of blood GNP interactions. As with many NPs, GNPs used in vivo are generally intended for intravenous delivery. Since blood is the first medium of interaction for these GNPs, it is imperative to understand blood protein and blood cell GNP interactions as these both ultimately connect to biodistribution and GNP utility as a nanomedical vehicle. Importantly, it is increasingly understood that GNPs and other nanomaterials have a synthetic, a biological and a physiological identity once they enter the blood due to their interaction with blood proteins as shown in Figure 1 and reviewed in Walkey and Chan [9] . The conversion of synthetic to biological identity refers to blood protein NP interactions (which may be in vitro), whereas the physiological response is concerned with blood cell NP interactions and the ultimate impact in vivo (i.e., biodistribution/toxicity). We therefore augment Walkey ' s review by presenting an overview of both blood protein and blood cell GNP interactions in this review. In some cases where no specific GNP blood studies exist, we draw the readers ' attention to studies conducted with other types of nanoparticles as reference.
Blood-NP interactions
Blood is often referred to as the " liquid organ " of the body. Its many functions include the transport and distribution of cells and molecules, defense against pathogens, wound healing, and thermoregulation of the body [10] . Blood mainly consists of two components: cells and
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Exposure Distribution Physiological response Figure 1 Blood NP interactions that determine the relationship between synthetic identity, biological identity, and physiological response. The synthetic identity is the size, shape, and surface chemistry of a NP post-synthesis. The biological identity is the size and aggregation state of the NP in an in vitro or in vivo physiological environment, along with the structure and composition of the protein corona. The physiological response is the subsequent in vivo interaction of NP protein aggregates with cells and molecules that determine biodistribution and toxicity. Reproduced from [9] with permission of The Royal Society of Chemistry.
plasma. Cells make up approximately 45% of the blood volume while plasma makes up the rest. Blood plasma is further made up of water (90% of plasma), soluble gases, metabolites, minerals and salts, low molecular weight components (lipids, carbohydrates, amino acids etc.), and proteins [10] . Thus blood-NP interactions can be divided into two major categories: plasma protein-NP interactions and blood cell-NP interactions. These are discussed in detail in the following sections.
Blood protein-NP interactions
According to the classical definition plasma proteins are, " those proteins carrying out their function in circulation " [11] . The newer classification of plasma proteins divide them into 8 categories: 1) secreted proteins that act in plasma, 2) immunoglobulins, 3) ' long-distance ' receptor ligands, 4) ' local ' receptor ligands, 5) temporary passengers, 6) tissue leakage products, 7) aberrant secretion, and 8) foreign proteins [12] . Plasma is the largest proteome in the body with about 50,000 molecular forms of classical plasma proteins and 10 million sequences of immunoglobulins alone [12] . With recent advances in protein detection techniques, about 300 plasma proteins have been identified with albumin being the most abundant (35 -50 mg/mL) and interleukein-6 being the least abundant (few pg/mL) [12] . This wide range of distribution in the protein concentration poses a tremendous challenge for purification, identification and characterization of plasma proteins let alone understanding their interaction with GNPs. Many of the proteins in blood are found in the serum, a protein solution that remains after plasma is allowed to clot and thus does not contain prothrombin and fibrinogen [12] . Thus, plasma is in some sense a parent blood-protein mixture and serum is its derivative. In the following review, studies with both plasma and serum interactions of NPs are included. For practical purposes, plasma proteins can be divided into functional groups, which according to Schaller can be grouped into 10 categories: 1) blood coagulation and fibrinolysis, 2) the complement system, 3) the immune system, 4) enzymes, 5) inhibitors, 6) lipoproteins, 7) hormones, 8) cytokine and growth factors, 9) transport and storage, and 10) additional proteins [10] . Interactions of NPs with any of the above protein groups can lead to downstream effects including immunological up or down regulation, biodistribution and clearance, cell signaling and activation. While NP interactions with the immune system, complement system, and coagulation system lead to some known downstream effects such as clearance and clotting, interactions with enzymes and inhibitors can lead to more subtle changes in degradation, metabolism or masking of molecular payload that affect biodistribution. Therefore it is important to understand the nature of plasma protein-NP interactions in terms of identification of proteins, binding kinetics, structural modifications of proteins upon binding, and resulting surface properties of NPs, although the best experimental and theoretical techniques to perform these studies are still under development [9] .
A number of in vitro studies have been conducted over the last decade describing the NP interactions with plasma/serum proteins. For instance, a large body of work also exists for liposomal particles, which have been recently investigated for surface charge density impact on the protein corona [13] . The liposomal work suggests that steric protection of particles using polymers such as PEG increases their blood circulation time by reduction in opsonization. Here, opsonization refers to the adsorption of plasma proteins that are capable of interacting with specific membrane receptors on the surface of monocytes and tissue macrophages, which in turn makes NPs visible to these cells for phagocytic uptake [14] . The proteins responsible for this process, called opsonins, are often part of the plasma protein functional groups such as the complement system, immunoglobulins, and apolipoproteins.
Several polymers such as PEG, poloxamer-407 and poloxamine-908 have been considered for NP coating to provide steric hindrance from opsonins. Gaucher et al. showed that when NPs coated with PEG or polyvinyl pyridine (PVP) are incubated with single protein solutions such as albumin, they show similar adsorption pattern [15] ; however, when incubated in serum PEGylated NPs show far less protein adsorption compared to PVP coated NPs. Leroux et al. showed by an elegant 2D electrophoresis approach that PEG coated and uncoated biodegradable NPs differed in two gel spots which may refer to specific apolipoproteins [16] . Using the same technique, Gref et al. showed that as long as the particle surface is protected by PEG, protein adsorption is not affected by the core material of the particle [17] . This is important as it suggests that PEG coating can be standardized such that a variety of different core particles with the same shape and size can be designed to interact similarly with blood. They further showed that PEG chain length (molecular weight-MW) and density have a strong impact on the amount of protein adsorbed. For example, the maximal reduction in protein adsorption was achieved when PEG MW 5000 and surface PEG density of 2% -5% was used [17] . They also found that albumin, fibrinogen, IgG, Ig light chains, and the apolipoproteins, apoA-I, and apoE were the most abundant in the protein corona around NPs [17] . Even when NPs are not PEGylated, albumin and fibrinogen have been shown to be the most abundant bound proteins. For example, Gessner et al. demonstrated that latex particles with increasing surface hydrophobicity showed higher protein adsorption with albumin and fibrinogen [18] .
Further work in this area is concerned not only with the identity and abundance of the protein, but also the binding kinetics of the protein to the nanoparticle [9, 19] . Cedervall et al. point out that the composition of the nanoparticle protein corona at any given time is dependent upon the concentration of proteins, and the kinetic and equilibrium constants of each protein in the plasma [20] . Using an array of mass spectroscopy and chromatography techniques, they tested the effect of surface hydrophobicity and size (curvature) on the identity and affinity of the bound proteins on polymeric compositions of N-isopropylacrylamide (NIPAM) and N-tert-butylacrylamide (BAM). They concluded that both the size and hydrophobicity of NPs have an impact on total bound protein; however, only hydrophobicity affects the protein binding affinity. Their chromatography results also showed that apolipoproteins bind to NP surface with greater affinity than albumin [20, 21] . Therefore, NP solutions that were washed multiple times showed higher bound albumin initially and a decrease in binding with subsequent washes [20] . Thus, if the protein corona on the NP were to be analyzed after a single wash, it may seem that albumin is the most abundant protein in the corona despite the uncertainty of how long it remains attached to NP in static conditions. Unfortunately, Cedervall and colleagues note that the association and dissociation rates of proteins cannot be detected reliably in complex plasma with the existing methods [21] . Nevertheless, some studies have determined the number and amount of proteins that adsorb to GNPs.
For instance, Dobrovolakaia identified a total of 69 plasma proteins that bind to the surface of citrate stabilized 30 nm and 50 nm GNPs [22] . Out of these 60 proteins, there were 7 that exclusively bound to 50 nm GNPs and 34 that exclusively bound to 30 nm GNPs. Complement factor 3 (C3) was shown to bind both GNPs; however, there was no indication of this leading to the activation of the complement system, which was tested with bioassays such as ELISA. Interestingly, fibrinogen was found to be the most abundant protein on both particles, not albumin. This is suggested to be due to the high isoelectric point of fibrinogen which is attracted to the anionic surface of the citrated GNPs [22] . In contrast, Casals et al. showed that for their 4 -40 nm citrated GNPs, albumin was the highest binding protein [23] . However, their study was performed in cell culture media rather than human plasma, which is typically supplemented with fetal bovine serum (FBS).
Similar to Dobrovolaskaia et al., they used dynamic light scattering (DLS) to show that the hydrodynamic diameter of GNPs increases upon formation of protein corona that progresses from a " soft " shell to an irreversible or " hard " shell over time [22, 23] . Using an anti-albumin antibody it was shown that bound albumin remains intact (i.e., not denatured) and that the increase in diameter is not due to protein or particle aggregation [23] .
Despite this, it is possible that proteins do denature or unfold upon binding or adsorbing to NPs [24, 25] . For instance, using albumin alone Treuell et al. found that the α -helical structures of albumin are destroyed in the presence of 20 nm citrated gold and silver NPs while it does not with polymeric NPs [24] . Zhang and colleagues also demonstrated aggregate formation with DLS, TEM and fluorescence microscopy in the lysozyme solution when incubated with GNPs (90 nm citrate stabilized) [25] . They suggest that partial unfolding of the protein on the surface of the GNP leads to interactions with more proteins, which in turn form a network of aggregates [25] . However, sufficient PEGylation of GNPs resolved the issue of aggregation [25] , again demonstrating the importance of PEGylation, or perhaps other polymer coatings, in the reduction of protein binding. One reason for this appears to be that plasma/serum proteins are attracted to hydrophobic and charged surfaces and a dense PEG layer makes the GNP surface more hydrophilic and charge neutral. Nevertheless, while PEGylated particles have longer blood circulation than un-PEGylated, they are still eventually opsonized and cleared from the blood stream [14, 26] .
More recent work on GNP serum and blood cell interactions continues to support the trends of this earlier work. For instance, Lacerda et al. showed that blood proteins such as albumin, fibrinogen, gamma globulin, histone, and insulin strongly associate to bare GNPs in the 5 -100 nm size range [27] . Walkey and Chan extend this to the more physiologically relevant PEGylated GNPs by documenting 70 different serum proteins that heterogeneously adsorb to the surface of these nanoparticles. The main factors that determine the relative amounts of each of these adsorbed proteins in both a " hard " and " soft " corona depends on nanoparticle size and PEG grafting density (PEG/nm 2 ) [9, 19] . The authors go on to show that these variations in serum protein adsorption lead to further differences in the mechanism and amount of nanoparticle uptake by macrophages, a cell line representative of the resident cells that clear nanoparticles in the Reticuloendothelial system (RES). Importantly, in a further review of this area Walkey and Chan discuss how the protein corona alters the size and interfacial composition of a nanomaterial, giving it a biological identity that is distinct from its synthetic identity ( Figure 1 ). The importance of the biological identity further helps determine the physiological response including biodistribution, signaling, kinetics, accumulation, and toxicity. Lartiqueet et al. make a similar argument for iron oxide nanoparticles and show that the protein corona and macrophage uptake depend on the protein environment (i.e., low plasma concentration vs. pure plasma) and also introduce a nanomagnetic approach to measure the corona growth and nanoparticle aggregation [28] .
Blood cell-NP interactions
The blood is not only filled with proteins, but is also comprised of cells which make up 45% of the blood by volume [29] . Blood cells can be divided in three types: Erythrocytes, Thrombocytes and Leukocytes as shown in Figure 2 . Erythrocytes or red blood cells (RBCs) make up 96% of total blood cells (4-5 × 10 9 cells/mL human blood) and their main function is oxygen transport [29] . RBCs have biconcave discoid shape with a diameter of approximately 7.5 μ m. They are devoid of nucleus and other cellular organelles and carry hemoglobin giving them the red color. Thrombocytes or platelets are also devoid of nucleus. There are about 2-3 × 10 8 platelets/mL of human blood (1% of total blood cells) [29] . They play a key role in blood coagulation and thrombosis during vascular injury. Recent findings also implicate the role of activated platelets in the host defense system by engulfment of bacteria via a series of interconnected channels on the platelet surface membrane (known as open canalicular system -OCS) [30, 31] . However, leukocytes or white blood cells (WBCs) are the class of blood cells that are primarily involved in the hostdefense against foreign materials and make up about 3% of all blood cells (4-8 × 10 6 leukocytes/mL human blood). Table 1 lists the WBC sub-types, their characteristics and functions [29, 32, 33] .
In vitro studies of blood cell-NP interactions are carried out in one of several systems: a human/animal cell line, primary human/animal blood cells, or simulated blood fluid. The following sections review GNP interactions with RBCs, platelets, and WBCs using other NP data when GNP data are not available .
Erythrocytes/RBCs
Studies of NP interactions with RBCs can be divided into two categories: 1) NP attachment and uptake; and 2) hemolysis or NP toxicity. There are only a handful of studies that describe the attachment/uptake of NPs to RBCs. In one such study, Rothen-Rutishauer et al. used fluorescent, gold, and titanium oxide (TiO 2 ) NPs to demonstrate the effect of size, charge and core material on the interactions of NPs with RBCs [34] . Using a variety of microscopic techniques they demonstrated that NP size was important in RBC uptake. According to this study, 1 μ m particles (regardless of their surface charge) associated with the RBC membrane, but they were never found inside the cells. Neutral, anionic and cationic NPs ( < 100 nm, including GNPs) however, were found inside the cells [34] . However, TiO 2 NPs were always taken up as small aggregates (of < 0.2 μ m) [34] . Membrane attachment of these NPs could be protein mediated (as in immune clearance of E. coli) [35] or charge mediated electrostatic binding. Such binding of NP to RBC surface can be used to increase the circulation time of NPs in blood. For example, Chambers et al. showed that polystyrene particles of varying sizes can irreversibly bind (up to 24 h) to the surface of human RBCs by simple mixing [36] . The blood circulation time of RBC bound NPs greatly improves compared to the free particles, but depends on the particle diameter. For example, 220 nm and 450 nm particles showed > 7 h of circulation time whereas particles larger than those were rapidly cleared from the circulation [36] . They also used a kinetic model to show that RBC attached NPs were cleared one-by-one from the circulation with RBCs carrying 3 or more particles showing the fastest clearance rate. It was speculated that the circulation time of the NPs could be further increased if they were covalently attached to the surface of RBCs. Hall and colleagues did exactly this by isolating two RBC binding peptides from a library displayed on fluorescent bacteria [37] . They conjugated these peptides to 220 nm polystyrene particles and showed 50 -90-fold improvement in the attachment of modified NPs to RBCs over non-conjugated NPs [37] . Most RBCs showed attachment of multiple NPs on their surface and 85% particle retention when subjected to shear stress of up to 10 Pa [37] . These studies, however, did not look at what kind of physiological effects, such as hemolysis, NP binding can have on RBCs.
In vitro studies of NP induced hemolysis, or RBC lysis, the most common physiological response to NPs, is a common nanoparticle toxicity assay [38] . Hemolysis is typically measured through hemoglobin release in the supernatant after incubation of NPs with either whole blood or washed RBCs. Though it may vary, the absorbance measurement for hemoglobin derivatives is generally performed at around 540 nm and is reported in % hemolysis based on positive and negative controls [38, 39] . Materials with < 5% of hemolysis are generally accepted as hemocompatible [40] . It has been shown that NP size and surface chemistry play an important role in the hemolysis [39 -41] . In general cationic surfaces induce greater hemolysis than anionic and neutral surfaces (in that order) [38] . This has been shown with a variety of NP systems including polystyrene, C60 fullerenes, dendrimers, and gold clusters [38, 42 -48] . It has been proposed that cationic particles induce toxicity by binding to the anionically charged RBC membrane and by inducing changes in the membrane morphology [40, 43] . For example, recently Zhao et al. showed that small mesoporous silica NPs (MSN) of ~100 nm in size bind to RBC membrane without inducing any deformability; however, large MSN (~600 nm) are engulfed by RBCs inducing local membrane deformation, cell shape change, and eventual hemolysis [40] . In addition to the size, surface porosity and presence of silanol groups play a major role in hemolytic effects of silica particles [40, 49] . It has been shown that MSN cause lesser degree of hemolysis compared to their porous and nonporous counterparts, which induce size and concentration dependent damage to the RBCs [49] . Both Lin et al. and Zhou et al. show that hemolytic tendencies of MSNs can be reduced by coating the surface of the NPs with PEG [40, 49] . Again, surface PEGylation has been shown to prevent hemolysis for a variety of NPs For a comprehensive analysis of NP interactions with RBCs, assays other than spectrophotometric measurement of hemoglobin are required. Transmission electron microscopy (TEM) has been utilized by a number of investigators to study the uptake of NPs in RBCs [34, 40, 52] . However, other functional assays investigating downstream effects should also be utilized. For example, Li et al. used RBC sedimentation and lipid peroxidation assays which measure RBC membrane integrity and agglutination, and reactive oxygen species (ROS) production, respectively [52] . Flow cytometry is another option for RBC morphology and ROS production studies [53] . Recently, atomic force microscopy (AFM) has also been utilized to study NP induced membrane deformations [48, 53] . Dobrovolaskaia et al. studied hemolysis of citrated GNPs of various sizes [38] . As highlighted in this study, it is important to note that GNPs absorb near 540 nm depending upon their size, which is where the hemoglobin absorbance is measured. Thus, traditional hemolysis assays must be run with caution and careful controls when GNPs are included [38] .
Thrombocytes/platelets
Studies of NP interactions with platelets can be divided in two categories: 1) NP attachment and uptake in platelets; 2) NP induced platelet activation and/or aggregation. In a classic study of type 1, it was shown that 300 nm latex particles are taken up by human platelets and can cause adenosine diphosphate (ADP) induced platelet aggregation [54] . The authors speculated that the uptake by platelets resembles phagocytosis of leukocytes [54] . In a series of subsequent studies, White et al. demonstrated that the uptake of particles by platelets is not phagocytosis, but merely sequestration in the platelet open canalicular system (OCS) [30, 31, 55] . Such uptake was also demonstrated by Xu et al. for gold-labeled chylomicron particles [56] . The important difference between the phagocytosis by leukocytes and the uptake by platelets is in the secretory granules of both cell types. In leukocytes, such as neutrophils, secretory granules fuse with the phagocytic vacuoles in which the ingested material is stored and thus their cytoplasm is protected from the toxic secretory materials. Contrary to that, platelets release their secretory materials from granules and dense bodies outside the cell in a process called degranulation [30] . Degranulation of platelets can also be considered activation and can be caused spontaneously or in response to external stimuli. Several activation agents, commonly known as agonists, have been identified and include ADP, thrombin, and collagen [57] .
Most in vitro studies of platelet-NP interactions performed in human platelet rich plasma (PRP) look at the impact of NPs exposure on platelet aggregation and activation as a sign of potential clot formation in vivo. Platelet aggregation is commonly studied using aggregometry in platelet rich plasma (PRP) which is normally a highly turbid solution. When platelets aggregate, the solution becomes clearer allowing the turbidity change to be measured optically. Commercial aggregometers can also monitor platelet activation by measuring ATP release using luminescence. Positive controls for activation such as mixed carbon NPs (MCN) showed concentration dependent platelet aggregation and activation (ATP release) that was comparable to the level of known agonists such as collagen and thrombin [58] . Often, platelet aggregation is accompanied by activation, but each phenomenon can occur on its own as well. For instance, multi walled carbon nanotubes (MWNT) and single walled carbon nanotubes (SWNT) induce platelet aggregation, but not activation [58] . Contrary to that, biological NPs (hydroxyapetite-HA and calcified NP) inhibited platelet aggregation but induced activation [59] . A similar observation was made for TiO 2 NPs [60] . On the other hand, other studies have shown polymeric NPs do not induce platelet aggregation in vitro [61, 62] . Furthermore, while latex NPs (50 nm) did not induce platelet aggregation alone, they did induce aggregation when conjugated to collagen related peptide (CRP, 31-mer) [63] .
Physicochemical properties of NPs have been shown to have an impact on platelet interactions. For example, it was proposed that the reason why carbon nanotubes but not spheres (C60 fullernes) cause platelet aggregation is because the shape of the nanotubes mimic the molecular bridges between platelets [58] . Furthermore, size appears to matter as large gold-silica nanoshells (150 nm) accentuate platelet aggregation while small 203 nm GNP do not [64] . Importantly, further size based studies [39, 41, 50] do not demonstrate appreciable trends in platelet aggregation. In contrast, surface charge and surface groups, particularly cationic particles, are known to increase aggregation/activation of platelets. For instance, incubation of platelets with positively charged polystyrene (PS) NPs showed an increase in P-selectin, a marker of platelet activation [65] . Interestingly another study showed that both positive and negatively charged 50 nm PS NPs induced platelet aggregation although by different mechanisms [45] . For instance, platelets exposed to cationic NPs displayed anionic phospholipids in their outer membrane; whereas, those exposed to negatively charged NPs, expressed phosphotidylserine -a marker of classical platelet activation pathway that induced platelet shape change [45] . Meyer et al. also showed no difference in platelet aggregation between their cationic and anionic NPs; however, they note that incubation of NPs with serum before exposing them to platelets may have caused reduction in surface charge [39] .
A reduction in NP opsonization by PEGylation appears to further prevent platelet aggregation. For instance, non PEGylated PLGA NPs have a concentration dependent effect on blood clotting time, speed of clot formation, coagulation time and strength of fibrin clot as measured by thromboelastography [44] . When these NPs were PEGylated, the effect on aforementioned parameters was greatly reduced [44] . Further, Gulati et al. showed that PEGylated PNIPAAM NPs, do not change the platelet dependent activity of extrinsic and intrinsic coagulation pathways [50] . PEGylated NPs also did not increase the concentration of fibrinogen which is the activator of the coagulation pathway [50] . Finally, PEGylation was also shown to reduce whole blood clotting time [51] . Thus, surface passivation of NPs by a dense layer of PEG reduces NP-platelet interactions. Importantly, one recent study now clearly shows that PEGylated GNPs can interact directly with platelets without leading to platelet aggregation by standard light aggregometry [66] . These results may need to be revisited with more sensitive quartz crystal microbalance that demonstrate aggregometry for a number of nanoparticles at concentrations that were undetectable by light aggregometry and flowcytometry [67] . In any case, there are few if any studies available on GNP-platelet interactions, which is puzzling considering the popularity of GNPs in pre-clinical and clinical settings. Perhaps the general understanding of gold being an inert material may have deterred investigators from considering these studies. Nonetheless, it is important to complete the characterization of GNP size, shape and surface characteristics in the context of platelet interactions and coagulation pathway.
Leukocytes/WBCs
Leukocyte-NP interaction in in vitro studies can be divided into two main categories: 1) studies with differentiated leukocyte cell lines, 2) studies with primary leukocytes isolated from blood/tissues. Though differentiated cell lines provide a controlled and convenient model for NP interaction studies, primary cells are more accurate representatives of the in vivo environment. Table 2 lists a review of NP-leukocyte interaction studies for differentiated cell lines. These studies evaluate the effect of NP physicochemical parameters such as size, charge, and surface chemistry on their uptake and downstream effects in these lines. A majority of these studies are conducted in murine macrophages and study cellular uptake and viability. Only a handful of studies focus on cell activation and found that NP internalization did not significantly impact the ROS, cytokine, or reactive nitric oxide species (RNS) [71, 75, 77] . In contrast primary cell studies suggest that NPs coated with biomolecules can activate the white blood cells depending upon the type of the molecule in the coat. These studies are discussed in detail below.
Primary leukocytes include freshly isolated lymphocytes, granulocytes, and monocytes as well as monocyte derived macrophages and dendritic cells, and peritoneal macrophages. NP-leukocyte interaction studies include NP uptake, intracellular localization, and cell activation. For example, Gref et al. tested how the PEGylation of poly (lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), and poly(caprolactone) (PCL) NPs affect their interactions with human blood cells (lymphocytes, monocytes, and granulocytes) [17] . As the PEG surface density increased from 1% to 4%, the size of the NPs increased, surface charges became neutral and uptake of NP reduced to negligible amounts [17] . Using PEGylated silica NPs in the same size range (~150 nm), Diaz et al. showed that binding of their NPs cause low level of ROS production in human lymphocytes and monocytes, but do not induce any toxicity [71] . Additionally, they tested these particles in mouse peritoneal macrophages and showed surface binding and a high level of ROS production during the initial 30 min [71] . However, the resulting toxicity was still very low, which shows that ROS production should not be used as a marker for cellular toxicity. For larger silica particles (270 nm and 2.5 μ m) an active uptake was demonstrated in the dendritic cells, which also resulted in the induction of immune regulatory markers [78] . Thus, size can affect not only the uptake of NP in cells, but can also play a role in cell activation. In addition to size, surface charge is important in NP uptake in leukocytes. Lunov et al. used 100 nm carboxyl or amine terminated groups to give NPs a net negative or positive charge, respectively [68] . Monocyte derived macrophages showed higher uptake of cationic NPs than anionic NPs in the absence of serum, but in the presence of serum, likely due to neutralization of the surface charge, this difference disappeared and uptake was reduced [68] . Lower uptake of NPs in the presence of serum seems to be a general trend, but it is not clear why Table 2 Summary of NP-leukocyte interaction studies. this occurs as one would expect opsonization to make NPs more recognizable to leukocytes. A number of further studies investigate specific leukocyte-GNP interactions. For example, the effect of bioactive coatings on GNP interactions with murine peritoneal macrophages was evaluated by Krpeti ć and colleagues [79] . GNPs coated with serotonin and melatonin showed high uptake in macrophages but GNP coated with L-DOPA showed no uptake. Macrophages have receptors for melatonin and they recognize platelets that contain high levels of serotonin, which explains the recognition of these molecules by macrophages; whereas, L-DOPA is the specific mediator for central nervous system and thus likely not recognized by the macrophages tested here [79] . Presence of such biomolecules on the GNP surface can lead to downstream effects by leukocytes, once the NPs are internalized. Bast ú s and colleagues showed that while 10 nm uncoated GNPs and peptides by themselves do not induce any cytokine production in bone marrow derived macrophages, peptide conjugated GNPs do [80] . Thus macrophage induced production of TNF-α , IL1-β , and nitric oxide (NO) is independent of peptide size and polarity, but varies based on the peptide sequence. Despite this, the viability of macrophages remained unaffected by the peptide conjugated GNPs [80] .
More recently Bartneck and colleagues have conducted a more comprehensive study of the effect of GNP shape (i.e., rod), surface charge and coating (PEO vs. CTAB) on uptake and activation of human blood primary leukocytes [81, 82] . A major finding of these studies was that neutrophils extracellular trap (NET) formation occurs within 15 min of exposure to GNPs independent of their shape and charge [81] . Though NET formation is not dependent on physicochemical properties of GNPs, the trapping was shown to be more efficient for nanorods and positively charged GNPs [81, 82] . Since there is an evidence for NET formation in vivo [83] , this could be an effective mechanism for GNP blood clearance. Monocytes and monocyte derived macrophages and dendritic cells also formed these networks but not as efficiently as neutrophils. Macrophages were shown to be more effective at taking up GNPs than the parent monocytes. Generally PEO coating reduced GNP uptake; however, after 7 days of incubation in serum, the uptake was comparable to CTAB coating owing to the eventual opsonization of PEO coated GNPs. Using uptake inhibitors macropinocytosis was shown to be the mechanism of uptake [82] . Furthermore, surface charge and shape had noticeable effects on cytokine production. For example, positively charged nanorods exhibited anti-inflammatory properties; whereas negatively charged groups induced pro-inflammatory events [82] .
The authors speculate that monocytes may have the ability to take up GNPs in circulation, migrate into tissue and then differentiate into macrophages [82] . However, to our knowledge no in vivo studies exist that can explain these phenomena.
The need for in vivo blood GNP interaction studies
In vitro investigations confirm the importance of interactions between nanoparticles (i.e., size, shape and charge), plasma proteins (i.e., fibrinogen, albumin, apolipoprotein etc.) and blood cells. The proteins in particular are key in creating a " biological identity " in the blood [9, 84] . Here, the influence of PEGylation and PEG density on the biological identity and ensuing vivo biodistribution remain to be fully clarified [84 -86] . For instance, in vitro work shows that fibrinogen binding to negatively charged GNPs is highly dependent on the surface density of the polymer and can further lead to activation of Mac-1 receptors on monocytic cells (THP-1) and induction of inflammatory cytokines [87] . These data and more suggest that protein-NP interactions can change the way cells and therefore tissues " see " the particle [85, 88, 89] . Importantly the majority of these studies are conducted in single protein solutions and do not represent the actual complexity that the NP would face in vivo in circulating blood/plasma. For example, in vitro studies have suggested that the binding of complement factors on NP surface does not lead to complement activation in vitro [22] . However, recent reports by Moghimi et al. indicate that intravenous injection of PEGylated NPs may activate complement system due to the generation of anti-PEG antibodies in vivo [26] .
One of few in vivo studies was recently performed by Shah et al. that was unable to demonstrate a statistically significant complement activation for PEGylated GNPs in vitro or in vivo [66] . More specifically, this work showed that 30 nm PEGylated gold NPs (GNPs) interact not only with blood proteins as thought before but also with blood cells (especially platelets and monocytes) in vivo as shown in Figure 3 . Further, GNP PEGylation allowed longer blood circulation times that in turn correlated strongly with tumor uptake in tumor burdened mice. Resident macrophages were primarily responsible for the bulk of GNP uptake in liver while spleen uptake was highly surface property dependent and appears to involve macrophages and cellular interaction between the red and white pulp. While preliminary in nature, this study clearly shows that the PEG layer is critical to blood interactions and eventual tumor and RES organ biodistribution in vivo. This work and several reviews [85, 86] are now calling for further work in vivo using pre-clinical models to characterize blood protein GNP interactions. Specifically, the following questions require answer to move the field forward: 1) How do GNP physicochemical properties affect their interactions with plasma proteins in circulation? 2) What are the downstream effects of plasma protein-GNP interactions (inflammation, coagulation, complement activation)? 3) How does the mechanism of protein binding affect the biodistribution of GNPs in vivo? Figure 4 shows several scenarios that can help guide these studies of GNP interactions with moving blood in the future. Plasma-protein binding (or opsonization) can lead to GNP recognition and clearance by the RES or circulating blood cells. Opsonin mediated binding of GNP to circulating blood cells and subsequent cell clearance from the blood-stream is a likely clearance mechanism for most GNPs. 
Conclusions
Based on this review, we can draw some general conclusions about the blood-NP interactions based on in vitro experiments as a function of NP physicochemical properties: 1. Charged surfaces show higher interactions with blood than neutral surfaces. 2. Positively charged NPs react more aggressively with plasma proteins and blood cells. 3. The impact of NP size and shape on blood interactions
is not yet clear. 4. Bioactive molecules tend to activate blood cells depending upon their composition. 5. PEGylation reduces protein binding to NP surface, decrease hemolysis and platelet aggregation, and reduces uptake by leukocytes.
However, it is not clear if these conclusions will hold in in vivo systems due to the complexity of the in vivo environment. In vitro experiments allow controlled, fast, and cost efficient assessment of NP physicochemical properties and their interactions with blood. In vivo studies of blood-NP interactions are scarce to none, especially for GNPs. Studies described here provide some insight into blood-NP interactions; however, a correlation would have to be established between in vitro studies and future in vivo studies. Specifically, systematic in vitro studies are going to be needed to generalize the results of in vivo studies, but in vivo studies are needed to confirm that the in vitro results are relevant in the more complex in vivo environment. Blood-GNP interaction is central to the idea of in vivo biodistribution of GNPs. Thus, there is an immediate need for mechanistic studies that can link the observed GNP biodistribution behavior in vivo to the interaction of the GNPs with blood proteins and blood cells. 
Figure 4
Moving blood-GNP interactions (right to left). Upon intravenous injection, GNP can interact with blood-proteins or blood cells directly. Blood-protein interactions may lead to binding of these proteins to GNP surface, referred to as opsonization, which may make them recognizable by circulating blood cells and/or RES system, both of which can lead to their clearance from the blood stream. Alternatively, if GNPs aggregate in the physiological environment, the increase in their size due to aggregation may also render them susceptible to uptake by blood cells and macrophages in the RES system.
